Literature DB >> 10608756

Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group.

R Chuachoowong1, N Shaffer, W Siriwasin, P Chaisilwattana, N L Young, P A Mock, S Chearskul, N Waranawat, T Chaowanachan, J Karon, R J Simonds, T D Mastro.   

Abstract

Human immunodeficiency virus (HIV) levels in cervicovaginal lavage (CVL) and plasma samples were evaluated in relation to perinatal transmission in a randomized placebo-controlled trial of brief antenatal zidovudine treatment. Samples were collected at 38 weeks' gestation from 310 women and more frequently from a subset of 74 women. At 38 weeks, after a 2-week treatment period, CVL HIV-1 was quantifiable in 23% and 52% of samples in the zidovudine and placebo groups, respectively (P<.001). The perinatal transmission rate was 28.7% among women with quantifiable CVL HIV-1 and high plasma virus levels (>10,000 copies/mL) and 1% among women without quantifiable CVL HIV-1 and with low plasma virus levels (P<.001). A 1-log increase in plasma HIV-1 increased the transmission odds 1.8 and 6.1 times (95% confidence interval, 0.9-3.5 vs. 2.4-15.4) for women with and without quantifiable CVL HIV-1, respectively (P=.03). CVL HIV-1 is an independent risk factor for perinatal HIV-1 transmission.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10608756     DOI： 10.1086/315179

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  25 in total

1.  Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments.

Authors:  Dorothy Mbori-Ngacha; Barbra A Richardson; Julie Overbaugh; Dana DeVange Panteleeff; Ruth Nduati; Matt Steele; Grace John-Stewart
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

2.  Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals.

Authors:  Elfriede Agyemang; Amalia S Magaret; Stacy Selke; Christine Johnston; Larry Corey; Anna Wald
Journal:  J Infect Dis       Date:  2018-10-20       Impact factor: 5.226

3.  Validation of performance of the gen-probe human immunodeficiency virus type 1 viral load assay with genital swabs and breast milk samples.

Authors:  Dana DeVange Panteleeff; Sandra Emery; Barbra A Richardson; Christine Rousseau; Sarah Benki; Sharon Bodrug; Joan K Kreiss; Julie Overbaugh
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

4.  Diversity, divergence, and evolution of cell-free human immunodeficiency virus type 1 in vaginal secretions and blood of chronically infected women: associations with immune status.

Authors:  Sharon T Sullivan; Usha Mandava; Tammy Evans-Strickfaden; Jeffrey L Lennox; Tedd V Ellerbrock; Clyde E Hart
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Fetal immune activation to malaria antigens enhances susceptibility to in vitro HIV infection in cord blood mononuclear cells.

Authors:  Kevin Steiner; Latoya Myrie; Indu Malhotra; Peter Mungai; Eric Muchiri; Arlene Dent; Christopher L King
Journal:  J Infect Dis       Date:  2010-09-15       Impact factor: 5.226

6.  Quantification of genital human immunodeficiency virus type 1 (HIV-1) DNA in specimens from women with low plasma HIV-1 RNA levels typical of HIV-1 nontransmitters.

Authors:  Sarah Benki; R Scott McClelland; Sandra Emery; Jared M Baeten; Barbra A Richardson; Ludo Lavreys; Kishorchandra Mandaliya; Julie Overbaugh
Journal:  J Clin Microbiol       Date:  2006-10-18       Impact factor: 5.948

Review 7.  Antiretroviral therapy in pregnancy: a focus on safety.

Authors:  G P Taylor; N Low-Beer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 8.  Advances in prevention of mother-to-child HIV transmission.

Authors:  Chokechai Rongkavilit; Basim I Asmar
Journal:  Indian J Pediatr       Date:  2004-01       Impact factor: 1.967

9.  Quantitation of human immunodeficiency virus type 1 RNA loads in cervicovaginal secretions in pregnant women and relationship between viral loads in the genital tract and blood.

Authors:  S García-Bujalance; G Ruiz; C Ladrón De Guevara; J M Peña; I Bates; J J Vázquez; A Gutiérrez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-20       Impact factor: 3.267

10.  Comparison of washing and swabbing procedures for collecting genital fluids to assess shedding of human immunodeficiency virus type 1 (HIV-1) RNA in asymptomatic HIV-1-infected women.

Authors:  Laurent Andréoletti; Gérard Grésenguet; Nicolas Chomont; Mathieu Matta; Yann Quiniou; Ali Si-Mohamed; Laurent Bélec
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.